410 related articles for article (PubMed ID: 29844297)
1. Immunotherapy for Gastric Cancer: Time for a Personalized Approach?
Dolcetti R; De Re V; Canzonieri V
Int J Mol Sci; 2018 May; 19(6):. PubMed ID: 29844297
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive multi-omics analysis of pyroptosis for optimizing neoadjuvant immunotherapy in patients with gastric cancer.
Wang JB; Gao YX; Ye YH; Zheng QL; Luo HY; Wang SH; Zhang T; Jin QW; Zheng CH; Li P; Lin JX; Chen QY; Cao LL; Yang YH; Huang CM; Xie JW
Theranostics; 2024; 14(7):2915-2933. PubMed ID: 38773976
[No Abstract] [Full Text] [Related]
3. Immunotherapy of gastric cancer: Past, future perspective and challenges.
Xie J; Fu L; Jin L
Pathol Res Pract; 2021 Feb; 218():153322. PubMed ID: 33422778
[TBL] [Abstract][Full Text] [Related]
4. Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy.
Subhash VV; Yeo MS; Tan WL; Yong WP
J Immunol Res; 2015; 2015():308574. PubMed ID: 26579545
[TBL] [Abstract][Full Text] [Related]
5. Oxidative stress in the tumor microenvironment in gastric cancer and its potential role in immunotherapy.
Yu Y; Wu Y; Zhang Y; Lu M; Su X
FEBS Open Bio; 2023 Jul; 13(7):1238-1252. PubMed ID: 37171226
[TBL] [Abstract][Full Text] [Related]
6. Current status of immune checkpoint inhibitors for gastric cancer.
Kono K; Nakajima S; Mimura K
Gastric Cancer; 2020 Jul; 23(4):565-578. PubMed ID: 32468420
[TBL] [Abstract][Full Text] [Related]
7. Progress and prospects of immune checkpoint inhibitors in advanced gastric cancer.
Zeng Z; Yang B; Liao Z
Future Oncol; 2021 Apr; 17(12):1553-1569. PubMed ID: 33397136
[TBL] [Abstract][Full Text] [Related]
8. Cytolytic activity score as a biomarker for antitumor immunity and clinical outcome in patients with gastric cancer.
Hu Q; Nonaka K; Wakiyama H; Miyashita Y; Fujimoto Y; Jogo T; Hokonohara K; Nakanishi R; Hisamatsu Y; Ando K; Kimura Y; Masuda T; Oki E; Mimori K; Oda Y; Mori M
Cancer Med; 2021 May; 10(9):3129-3138. PubMed ID: 33769705
[TBL] [Abstract][Full Text] [Related]
9. Research progress on the immune microenvironment and immunotherapy in gastric cancer.
Mou P; Ge QH; Sheng R; Zhu TF; Liu Y; Ding K
Front Immunol; 2023; 14():1291117. PubMed ID: 38077373
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in immune therapies for gastric cancer.
Olnes MJ; Martinson HA
Cancer Gene Ther; 2021 Sep; 28(9):924-934. PubMed ID: 33664460
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapeutic Strategies for Gastric Carcinoma: A Review of Preclinical and Clinical Recent Development.
Abozeid M; Rosato A; Sommaggio R
Biomed Res Int; 2017; 2017():5791262. PubMed ID: 28781967
[TBL] [Abstract][Full Text] [Related]
12. Utilizing precision medicine to modulate the prostate tumor microenvironment and enhance immunotherapy.
Olson B; Patnaik A
Urol Oncol; 2019 Aug; 37(8):535-542. PubMed ID: 30503851
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in Esophagogastric Cancer: Treatment Landscape, Challenges, and New Directions.
Balmaceda NB; Kim SS
J Gastrointest Cancer; 2024 Mar; 55(1):153-167. PubMed ID: 38127239
[TBL] [Abstract][Full Text] [Related]
14. Impacts and mechanisms of metabolic reprogramming of tumor microenvironment for immunotherapy in gastric cancer.
Zhao L; Liu Y; Zhang S; Wei L; Cheng H; Wang J; Wang J
Cell Death Dis; 2022 Apr; 13(4):378. PubMed ID: 35444235
[TBL] [Abstract][Full Text] [Related]
15. The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target.
Gambardella V; Castillo J; Tarazona N; Gimeno-Valiente F; Martínez-Ciarpaglini C; Cabeza-Segura M; Roselló S; Roda D; Huerta M; Cervantes A; Fleitas T
Cancer Treat Rev; 2020 Jun; 86():102015. PubMed ID: 32248000
[TBL] [Abstract][Full Text] [Related]
16. CAR T‑cell therapy for gastric cancer: Potential and perspective (Review).
Long B; Qin L; Zhang B; Li Q; Wang L; Jiang X; Ye H; Zhang G; Yu Z; Jiao Z
Int J Oncol; 2020 Apr; 56(4):889-899. PubMed ID: 32319561
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in gastric cancer.
Matsueda S; Graham DY
World J Gastroenterol; 2014 Feb; 20(7):1657-66. PubMed ID: 24587645
[TBL] [Abstract][Full Text] [Related]
18. Combining single-cell sequencing data to construct a prognostic signature to predict survival, immune microenvironment, and immunotherapy response in gastric cancer patients.
Hu B; Meng Y; Qu C; Wang BY; Xiu DR
Front Immunol; 2022; 13():1018413. PubMed ID: 36300104
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
20. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
